



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Analysis of the predictive factors for a critical illness of COVID-19 during treatment - relationship between serum zinc level and critical illness of COVID-19 –



Yukako Yasui^{a,*}, Hiroyuki Yasui^{b,*}, Kumiko Suzuki^c, Takako Saitou^c, Yoshiki Yamamoto^a, Toshihiko Ishizaka^a, Kouji Nishida^d, Shingo Yoshihara^e, Iwao Gohma^d, Yoshihiko Ogawa^e

^a Department of Pharmacy, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai City, Osaka, 593-8304, Japan

^b Department of Analytical & Bioinorganic Chemistry, Division of Analytical & Physical Chemistry, Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto 607-8414, Japan

^c Department of Clinical Laboratory, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai City, Osaka, 593-8304, Japan

^d Department of Respiratory Medicine, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai City, Osaka, 593-8304, Japan

^e Department of Infectious Diseases, Sakai City Medical Center, 1-1-1 Ebaraji-cho, Nishi-ku, Sakai City, Osaka, 593-8304, Japan

ARTICLE INFO

Article history:

Received 19 July 2020

Received in revised form 28 August 2020

Accepted 2 September 2020

Keywords:

COVID-19

Serum zinc

Predictive factors

Logistic regression analysis

Critical illness

Japan

ABSTRACT

Objectives: Because most severely ill patients with COVID-19 in our hospital showed zinc deficiency, we aimed to examine the relationship between the patient's serum zinc level and severe cases of COVID-19. **Methods:** Serum zinc <70 µg/dL was defined as the criterion for hypozincemia, and patients continuously with serum zinc <70 µg/dL were classified in the hypozincemia cohort. To evaluate whether hypozincemia could be a predictive factor for a critical illness of COVID-19, we performed a multivariate analysis by employing logistic regression analysis.

Results: Prolonged hypozincemia was found to be a risk factor for a severe case of COVID-19. In evaluating the relationship between the serum zinc level and severity of patients with COVID-19 by multivariate logistic regression analysis, critical illness can be predicted through the sensitivity and false specificity of a ROC curve with an error rate of 10.3% and AUC of 94.2% by only two factors: serum zinc value ($P = 0.020$) and LDH value ($P = 0.026$).

Conclusions: Proper management of the prediction results in this study can contribute to establishing and maintaining a safe medical system, taking the arrival of the second wave, and the spread of COVID-19 in the future into consideration.

© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

A study has reported that COVID-19 in a specific portion of inpatients has become severe (Wu et al., 2020a). Other studies have indicated that among those severe cases, the mortality rate of patients who require ICU care is substantially high, at a rate of 32%–72% (Huang et al., 2020; Wu and McGoogan, 2020b; Yang et al., 2020; Zhou et al., 2020). Considering the expected next wave and spread of infection in the future, having the ability to predict the influx of inpatients with COVID-19 using multiple basic factors will have a significant impact in terms of securing ICU availability and subsequent decisions required in medical institutions who treat

patients with COVID-19. When this becomes feasible, it will enable medical institutions to preliminarily categorize patients whose symptoms may potentially progress to severe and focus on the treatment from an early stage. Therefore, it is considered essential to examine highly predictive clinical factors to forecast immediately after hospitalization if patients will be cured while remaining within the mild to moderate range or become critically ill during treatment.

Based on previous reports (Zhang et al., 2020; Li et al., 2020; Jordan et al., 2020), the Sakai City Medical Center has been treating patients using the following risk factors for critical illness: age ≥ 65 years, obesity (BMI ≥ 25), history of diseases such as hypertension, respiratory disease, diabetes, cardiovascular disorders, and LDH ≥ 445 IU/L (Li et al., 2020). Additionally, levels of ferritin, KL-6, CRP, and D-dimer have been used as observation items since the beginning. As it has been reported that more than a certain number of cases of dysosmia and dysgeusia were observed in

* Corresponding authors.

E-mail addresses: yasui-yaku@sakai-hospital.jp (Y. Yasui), yasui@mb.kyoto-phu.ac.jp (H. Yasui).

addition to fever, malaise, cough, etc. as the initial symptoms of COVID-19, it was assumed that hypozincemia—a condition deeply associated with the onset of dysgeusia—had occurred in patients (Kodama et al., 2016). Since it had been reported that immuno-compromised and inflammatory states are caused by hypozincemia (Kodama et al., 2016), serum zinc concentration (serum zinc) was added as a test item in COVID-19 patients from the middle period of the pandemic in Japan.

Zinc is one of the “essential minerals” in the human body. Zinc deficiency in the body due to various causes is called hypozincemia. Hypozincemia symptoms include dysgeusia, loss of appetite, dermatitis, hair loss, anemia, and stomatitis. The Japanese Society of Clinical Nutrition suggests that a serum zinc level of 80–130 µg/dL is defined as normal, a level of 60–80 µg/dL is defined as subclinical zinc deficiency, and a level of <60 µg/dL is defined as clinical zinc deficiency in Japan (Kodama et al., 2016). In contrast, in the Harrison's Principles of Internal Medicine, used as an international standard indicator, clinical zinc deficiency is defined <70 µg/dL (10.7 µmol/L) (Russell et al., 2018). In this study, the zinc deficiency state was set at <70 µg/dL to enable direct comparison with domestic and international information.

Based on the measurement results of serum zinc levels in patients with COVID-19 in our hospital, almost all severe cases showed subclinical or clinical zinc deficiency, and prolonged hypozincemia is also considered a risk factor for critical illness of COVID-19. In response to the above results, we aimed to examine the relationship between the patient's serum zinc level and severe cases of COVID-19 in detail and to evaluate whether hypozincemia could be a predictive factor for a critical illness of COVID-19.

Methods

Patients information

The research was conducted by identifying 62 patients with COVID-19 who were admitted to the Sakai City Medical Center from March 24 to May 24, 2020, and then forming a sub-group of 29 patients who underwent a determination of the serum zinc concentration. According to the follow-up observation after hospital admission, all patients (62 patients) were classified into

two groups: mild/moderate and severe. The classification criteria were based on the nine-score ordinal scale described in the COVID-19 therapeutic trial synopsis: (0) No clinical or virological evidence of infection; (1) No limitation of activities; (2) Limitation of activities; (3) Hospitalized, no oxygen therapy; (4) Hospitalized, oxygen by mask or nasal prongs; (5) Hospitalized, non-invasive ventilation or high-flow oxygen; (6) Hospitalized, intubation and mechanical ventilation; (7) Hospitalized, ventilation + additional organ support—pressors, RRT, ECMO; (8) Death. Patients (0) to (5) were classified into the mild/moderate group, and those who fall within (6) to (8) were classified into the severe group. Further, death was not observed in all hospitalized patients this time.

Blood sampling and measurement of serum zinc

Serum zinc was measured several times at the time of blood sampling on the first day of hospitalization and two to three days later. When measuring serum zinc, it is required to pay attention to the influence of diurnal variation and diet; it can also be affected by stress and hormone conditions. Therefore, blood sampling and measurement were conducted on multiple days on an empty stomach early in the morning after hospitalization, and centrifugation of blood was performed as early as possible after blood collection. To determine serum zinc, we used Accuras Auto Zn (Shino-Test Corporation, Tokyo), a test kit for pharmaceuticals for external diagnosis, developed to measure zinc concentration in serum (Higurashi, 2015), using the automatic analyzer (Automatic Analyzer AU5800, Beckman Coulter, Inc., Tokyo, Japan) at the Sakai City Medical Center. We defined the concentration of serum zinc <70 µg/dL (10.7 µmol/L) as the criterion for hypozincemia, and patients with serum zinc <70 µg/dL continuously after the first and second measurements were classified in the hypozincemia cohort.

Estimates of other clinical laboratory data

LDH and ferritin levels and KL-6 in patients' serum were measured using the automatic analyzer (AU5800, Beckman Coulter, Inc.) as well. White blood cell, neutrophil, and lymphocyte counts were also measured using a blood cell count device

Table 1
Demographic, clinical, and laboratory characteristics of all patients with COVID-19.

Characteristics or Condition	Total patients	Mild and Moderate	Severe (Intubation)	χ^2	P value
	(n = 62)	(n = 49, 79%)	(n = 13, 21%)		
Male sex	34	26 (53%)	8 (62%)	0.30	0.585
Age \geq 65 years	17	10 (20%)	7 (54%)	5.77	0.016 *
Obesity (BMI \geq 25)	25	21 (43%)	4 (31%)	0.62	0.430
Diabetes mellitus	13	7 (14%)	6 (46%)	6.30	0.012 *
HbA1c \geq 6.0%	28/61	17 (35%)	11 (85%)	9.97	0.002 **
Chronic kidney disease	6	4 (8.2%)	2 (15%)	0.61	0.434
Liver disease	3	1 (2.0%)	2 (15%)	3.97	0.046 *
Hyperlipidemia	7	4 (8.2%)	3 (23%)	2.28	0.131
Cardiovascular disease	2	0 (0%)	2 (15%)	7.79	0.005 **
Hypertension	20	12 (24%)	8 (62%)	6.45	0.011 *
Respiratory disease	8	8 (89%)	0 (0%)	2.44	0.119
Palate disorder	12/32	10 (45%)	2 (20%)	1.90	0.168
LDH \geq 445 IU/L	11/61	5 (10%)	6 (46%)	8.84	0.003 **
Ferritin \geq δ :300 (φ :200) ng/mL	30/51	19 (49%)	11 (92%)	6.99	0.008 **
Laboratory Parameters	Total patients	Mild and Moderate	Severe (Intubation)	t-statistics	P value
Age (year)	62 (49, 13)	49.7 \pm 16.1	63.2 \pm 14.1	2.77	0.008 **
BMI (kg/m ²)	62 (49, 13)	24.6 \pm 4.5	26.6 \pm 6.9	1.24	0.218
HbA1c (%)	61 (48, 13)	6.0 \pm 1.0	6.7 \pm 1.1	2.20	0.032 *
LDH (IU/L)	61 (48, 13)	250 \pm 111	442 \pm 191	4.67	0.00002 **
Ferritin (ng/mL)	51 (39, 12)	386 \pm 393	1117 \pm 654	4.77	0.00002 **

Ferritin \geq 300 or 200 (ng/mL) corresponds to the male or female cases, respectively. Laboratory data are expressed as the means \pm standard deviations (SDs).

Statistical significance: *, $P < 0.05$, **, $P < 0.01$. Categorical and variable data analyses were performed by the chi-squared and Student-t-tests, respectively.

(Multiple Automated Blood Cell Counter XN-3000, Sysmex Corporation); D-dimer was measured using a blood-coagulation-ability measurement device (CS-5100, Sysmex Corporation). From the medical record data, the patients' sex, age, obesity (BMI \geq 25), history of previous disease (diabetes, chronic renal disorder, liver disease, dyslipidemia, cardiovascular disease, hypertension, respiratory disease, taste abnormality), as well as HbA1c were verified at the time of admission.

Statistical analysis

We examined each of 21 clinical factors, including the items mentioned above and serum zinc level in the laboratory data, to identify whether the factors associated with the critical illness of COVID-19 were statistically significant. Regarding the statistical analysis between the two groups, the chi-square test was conducted for the categorical data items, and the Student-*t*-test was conducted for the numerical data items; $P < 0.05$ was determined as significant. The 29 subgroup patients with serum zinc data were divided into two groups, mild/moderate and severe, and the same statistical analysis was performed. Next, to confirm if each factor found to be significant between the two groups were confounding factors, an independence test using the chi-square value and correlation evaluation using univariate analysis were performed.

To examine to what extent clinical factors—recognized not as confounding but independent factors—had an impact on the critical illness of COVID-19 and if they can be used as factors predictive of aggravation, we performed a multivariate analysis by employing logistic regression analysis using clinical factors as explanatory variables and critical illness of COVID-19 as objective variables. Regarding the analysis results, the C-statistic by the area under the curve (AUC) of the ROC curve by logistic regression, the contribution rate by the square of the correlation coefficient, and the error rate were simultaneously evaluated; then, a variable selection was adopted in the case where the *P*-value of covariance for an explanatory variable is to be <0.2 . In reporting the calculation results, the regression coefficient of the covariate

employed in the multivariate analysis, its standard deviation, the Wald χ^2 value, the *P*-value, the odds ratio, and the 95% confidence interval of the odds ratio were used. All statistical analysis of the data was performed using Excel statistics (BellCurve for Excel, version 3.20, Stock Social Information Service, Tokyo, Japan).

Results

Table 1 (total patients) and Table 2 (patients with serum zinc data) show the results of the statistical analysis of clinical factors, which were obtained by dividing inpatients into two groups, respectively. Eight categorical factors have been determined as statistically significant between the two groups for all hospitalized patients (Table 1). The following factors are associated with critical illness: age \geq 65 years, diabetes, HbA1c \geq 6.0%, liver disease, cardiovascular disease, hypertension, LDH \geq 445 IU/L, and high ferritin (male: \geq 300 ng/mL, female: \geq 200 ng/mL, cutoff value). The significant numerical variables are actual age, HbA1c, LDH, and ferritin levels. The clinical factors reported in these results were similar to the ones that have already been reported in China, Europe, and the United States (Gandhi et al., 2020; Jordan et al., 2020; Li et al., 2020; Zhang et al., 2020; Zhu et al., 2020). In contrast, of the categorical factors shown in Table 2, the following four items have been determined as statistically significant and are associated with critical illness: HbA1c \geq 6.0%, cardiovascular disease, LDH \geq 445 IU/L, and serum zinc $<$ 70 μ g/dL. The significant numerical factors are LDH, ferritin, and serum zinc levels. Because of the smaller size of the sub-group with serum zinc level, compared to the whole group, there was no difference in the factors associated with critical illness, and fewer factors were identified.

The serum zinc levels in the subgroups are shown in Figure 1. There were three patients (14%) in the mild/moderate group and six patients (86%) in the severe group whose zinc level was below the cutoff value of zinc deficiency ($<$ 70 μ g/dL), indicating that the serum zinc level in the patients of the severe group was remarkably low. With the above results, we decided to perform an analysis to predict the critical illness of inpatients with COVID-19 for the next

Table 2
Demographic, clinical, and laboratory characteristics of the subgroups of patients with COVID-19.

Characteristics or Condition	Total patients	Mild and Moderate	Severe (Intubation)	χ^2	P value
	(n = 29)	(n = 22, 76%)	(n = 7, 24%)		
Male sex	16	12 (55%)	4 (57%)	0.01	0.904
Age \geq 65 years	11	7 (32%)	4 (57%)	1.45	0.229
Obesity (BMI \geq 25)	12	10 (45%)	2 (29%)	0.62	0.430
Diabetes mellitus	6	3 (14%)	3 (43%)	2.76	0.097
HbA1c \geq 6.0%	15	9 (41%)	6 (86%)	4.27	0.039 *
Chronic kidney disease	3	2 (9.1%)	1 (14%)	0.15	0.694
Liver disease	1	1 (4.5%)	0 (0%)	0.33	0.566
Hyperlipidemia	4	3 (14%)	1 (14%)	0.00	0.965
Cardiovascular disease	2	0 (0%)	2 (29%)	6.75	0.009 **
Hypertension	12	7 (32%)	5 (71%)	3.43	0.064
Respiratory disease	2	2 (9.1%)	0 (0%)	0.68	0.408
Palate disorder	12	10 (45%)	2 (29%)	0.62	0.430
LDH \geq 445 IU/L	7	2 (9.1%)	5 (71%)	11.27	0.0008 **
Ferritin \geq ♂:300 (♀:200) ng/mL	21	15 (68%)	6 (86%)	0.82	0.366
Zinc $<$ 70 μ g/dL	9	3 (14%)	6 (86%)	12.89	0.0003 **
Laboratory Parameters	Total patients	Mild and Moderate	Severe (Intubation)	t-statistics	P value
Age (year)	29 (22, 7)	54.3 \pm 17.5	62.7 \pm 15.3	1.14	0.264
BMI (kg/m ²)	29 (22, 7)	25.0 \pm 3.8	26.0 \pm 5.4	0.55	0.587
HbA1c (%)	29 (22, 7)	6.1 \pm 1.0	6.7 \pm 1.3	1.41	0.170
LDH (IU/L)	29 (22, 7)	283 \pm 99	495 \pm 165	4.19	0.0003 **
Ferritin (ng/mL)	29 (22, 7)	458 \pm 399	956 \pm 689	2.40	0.024 *
Zinc (μ g/dL)	29 (22, 7)	87.7 \pm 19.1	62.4 \pm 19.2	3.04	0.005 **

Ferritin \geq 300 or 200 (ng/mL) corresponds to the male or female cases, respectively.

Laboratory data are expressed as the means \pm standard deviations (SDs).

Statistical significance: *, $P < 0.05$, **; $P < 0.01$. Categorical and variable data analyses were performed by the chi-squared and Student-*t*-tests, respectively.




Figure 1. Comparison of serum zinc concentrations in patients with COVID-19 (n = 29) between the mild/moderate and severe (intubation) conditions. Statistical significance: $p < 0.01$ by Student-t test. The central red lines correspond to the mean values, and the upper and lower red lines correspond to the means + standard deviation (SDs) and means – SDs, respectively. The dotted line denotes the threshold concentration of hypozincemia as 70 µg/dL.

step, based on the multivariate analysis of the factors that showed significant differences between the two groups. First, to narrow down clinical factors used as covariates that have been determined as not confounding but independent factors, mutual confounding was evaluated by an independence test using the chi-square value and a correlation analysis using a univariate analysis. As a result, the following confounding factors have been identified: “age \geq 65 years vs. cardiovascular disease ($\chi^2 = 5.47, P = 0.02$),” “age \geq 65 years vs. hypertension ($\chi^2 = 4.59, P = 0.03$),” “diabetes vs. HbA1c \geq 6.0% ($\chi^2 = 14.33, P = 0.0002$),” “diabetes vs. liver disease ($\chi^2 = 3.97, P = 0.046$),” “LDH \geq 445 IU/L vs. high ferritin ($\chi^2 = 9.82, P = 0.002$),” “LDH value vs. ferritin value ($r=0.633, P < 0.001$),” and the factors strongly associated with critical illness had been narrowed down to three: “age \geq 65 years (or actual age), diabetes/HbA1c \geq 6.0% (or HbA1c level), and LDH \geq 445 IU/L (or LDH value) (Liang et al., 2020; Yan et al., 2020; Zhu et al., 2020).” Figure 2 shows a collinear relationship between the LDH and serum ferritin values that has been determined to be significant by univariate analysis as an example of confounding factors. Moreover, the identified confounding factors among the subgroup with the serum zinc was measured were as follows: “serum zinc <70 µg/dL vs.




Figure 2. Collinear relationship between the serum ferritin and LDH values in all patients (n = 62) with moderate correlation ($r = 0.633, P < 0.001$). Collinearity between the data of serum ferritin and LDH was statistically recognized because both parameters would be increased by the infection and inflammation.

cardiovascular disease ($\chi^2 = 4.77, P = 0.03$),” “diabetes vs. HbA1c \geq 6.0% ($\chi^2 = 7.06, P = 0.008$),” “LDH \geq 445 IU/L vs. high ferritin ($\chi^2 = 4.21, P = 0.04$),” “LDH value vs. ferritin value ($r=0.650, P < 0.001$).” The same three factors were found to be associated with critical illness in the sub-group: “HbA1c \geq 6.0%, hypozincemia (or serum zinc level), LDH \geq 445 IU/L (or LDH level).”

We next conducted a logistic regression analysis for all inpatients using data of three continuous variables of “actual age, HbA1c value, LDH value” as explanatory variables in the multivariate analysis and critical illness was set as the objective variable. Akaike’s Information Criteria (AIC), which is widely used when selecting the optimum result from multiple models based on statistical judgment, was applied to select the optimum model. A combination of the minimum AIC and a P-value of 0.2 or less for the covariate, including the constant term, was adopted. The results of the logistic regression analysis performed at that time are shown in Table 3, and the ROC curve generated using the logistic regression is shown in Figure 3. In the adopted model, the HbA1c value was rejected as an explanatory variable, and it was found that critical illness is predicted through the sensitivity and false specificity of a ROC curve with its error rate of 14.8% and AUC of 84.9% by two factors alone: actual age ($P = 0.088$) and LDH value ($P = 0.003$). Our predictive analysis for the overall patients in this study showed very similar results to those recently reported in China for predicting morbidity and mortality of patients with COVID-19 (Liang et al., 2020; Yan et al., 2020).

Conversely, for the patients in the sub-group with serum zinc level, logistic regression analysis was conducted using data of three continuous variables “serum zinc value, HbA1c value, LDH value” as explanatory variables and critical illness as the objective variable. The selection criteria for the optimum model has remained the same, and the results of the logistic regression analysis of the adopted model (the constant term is judged to be zero from AIC) are shown in Table 4, and the ROC curve is shown in Figure 4. Similarly, with the adopted model, the HbA1c value was rejected as an explanatory variable, and critical illness can be predicted through the sensitivity and false specificity of a ROC curve with an error rate of 10.3% and AUC of 94.2% by two factors alone: serum zinc value ($P = 0.020$) and LDH value ($P = 0.026$). The sub-group’s predictive results using serum zinc levels were found to substantially exceed those of overall patients.

Discussion

Recent research was reported from China on the severe disease and mortality of patients with COVID-19, in which 575 hospitals in China participated to develop risk prediction scores of the patients with a critical illness (ICU admission, invasive ventilation, and death) (Liang et al., 2020). Patients are categorized into the development cohort and the confirmation cohort comprising 1590 and 710 patients, respectively. In the actual calculation, the following ten items from 72 potential factors were finally adopted as independent predictors (numbers in parentheses are odds ratios). They include chest X-ray abnormality at admission (3.39), age (1.03), hemoptysis (4.53), dyspnea (1.88), consciousness disorder (4.71), number of comorbidities (1.60), history of cancer

Table 3

Estimated parameters based on the multivariate logistic analysis for predicting severe cases (intubation) using two factors, LDH, and age, among all patients (n = 61).

Factor	Coefficient	SE	Wald χ^2	P value	Odds ratio	95% CI
LDH	0.008	0.003	8.529	0.003	1.008	1.003–1.013
Age	0.047	0.028	2.909	0.088	1.049	0.993–1.107
intercept	–6.617	2.006	10.877	< 0.001	0.001	0.000–0.068

AUC = 0.849, $R^2 = 0.284$, correlation coefficient = 0.551, and error rate = 0.148.




Figure 3. Receiver operating characteristic (ROC) curve for all patients with COVID-19 ($n = 62$) by LDH and ages.

Table 4

Estimated parameters based on the multivariate logistic analysis for predicting severe cases (intubation) using two factors, LDH and serum Zn concentrations, among zinc-determined patients ($n = 29$).

Factor	Coefficient	SE	Wald χ^2	P value	Odds ratio	95% CI
Serum Zn	-0.106	0.046	5.421	0.020	0.899	0.823–0.983
LDH	0.016	0.007	4.950	0.026	1.016	1.002–1.031
intercept	0.000					

AUC = 0.942, $R^2 = 0.663$, correlation coefficient = 0.782, and error rate = 0.103.




Figure 4. Receiver operating characteristic (ROC) curve for patient subgroups with COVID-19 ($n = 29$) by LDH and serum Zn.

(4.00), neutrophil/lymphocyte ratio (1.06), LDH (1.002), and direct bilirubin (1.15). Of these, test values for only three factors from the blood samples were available: neutrophil/lymphocyte ratio, LDH, and direct bilirubin (Liang et al., 2020).

Similarly, it has been reported that a study by Chinese researchers on predicting mortality from blood samples attempted

machine learning with AI to identify biomarkers predicting mortality using blood samples from 485 patients in Wuhan. The research findings demonstrated that (values in parentheses indicate cutoff values), using three factors of high LDH (365 IU/L), high level of high-sensitive CRP (41.2 mg/L), and reduced lymphopenia (14.7%), predicting patient mortality has become feasible more than ten days earlier than prior readings, with an accuracy of less than 10% error rate (AUC 97.8% and 95.1% in the development and confirmation cohorts, respectively.) However, in practice, it has been reported that LDH alone has made it possible to identify many patients who require quick medical intervention (AUC 92.3%–94.2%) (Yan et al., 2020).

To summarize the above report, LDH level and white blood cell count (including neutrophil/lymphocyte ratio) have been identified as the most critical factors in blood sampling for predicting the severe disease state and mortality of patients with COVID-19 based on a large number of patients in China, which supported the results of this study. Actually, we found precisely the opposite relationships (data not shown) of LDH level with the number of neutrophil or that of lymphocyte where the former and latter were positive and negative, respectively, suggesting that activation of cellular immunity as the innate immune system might contribute to a rapid and non-specific increase of inflammation in the early phase of infection of COVID-19, rather than activation of killer and helper T-lymphocytes as the acquired immunity. White blood cells are the compartmental location site where zinc is distributed and stored at the maximum concentration (380–450 $\mu\text{g}/\text{mL}$) in circulating blood (Kodama et al., 2016). In patients with zinc deficiency or hypozincemia, a decrease in the white blood cell count can quickly occur after COVID-19, or it is assumed that it has already occurred before the infection.

In this study, no association between dysgeusia and hypozincemia was found in patients with COVID-19. In contrast, the results of an *in vitro* study in which zinc ion (Zn^{2+}) and ionophore were used in combination, originally reported its antiviral effect against SARS coronavirus (Velthuis et al., 2010). It has been proven that zinc ions directly inhibit the activity of the RNA-dependent RNA polymerase of SARS-CoV-1 to suppress the replication of viral genomic RNA and block the replication of viral particles as the mechanism of action (Velthuis et al., 2010). Compared with the target molecule for the mechanism of action of Remdesivir or Favipiravir against SARS-CoV-2, whose pharmacological effects are being evaluated in observational studies and clinical trials as potential therapeutic agents for COVID-19 (Guy et al., 2020; Sanders et al., 2020), the target molecule for the mechanism of action of zinc ion is the same molecule that is present in coronavirus; as a result, the effects of zinc ion using ionophore (Xue et al., 2014) and complexation (Sakurai et al., 2002; Sakurai et al. 2008) on SARS-CoV-2 is expected to be evaluated in the future. Besides, while the therapeutic effect of hydroxychloroquine on COVID-19 has remained uncertain (Geleris et al., 2020), it is possible to establish a working hypothesis in which hydroxychloroquine can demonstrate synergistic effects with zinc ion (Liu et al., 2020; Wang et al., 2020). However, it is necessary to prove the synergistic effect in an *in vivo* experimental system before determining the clinical therapeutic effects.

Conversely, zinc ion is known for its mechanism involving the activation of immune cells that regulate the promotion or suppression of cell-mediated immunity (Hirano et al., 2008). The intracellular zinc ion is reported to inhibit activation of phosphorylation of STAT3, which is a crucial molecule of intracellular signal transduction by IL-6 stimulation, resulting in the suppression of cytokine storm (Kitabayashi et al., 2010); zinc ion supplementation regulates the helper T2 lymphocyte-M2 macrophage activation pathway to promote anti-inflammatory effects (Kido et al., 2019). Although the immunocompromised state




Figure 5. Time-dependent changing profiles of serum zinc concentrations in four critically ill (severe) patients after pathogenesis of COVID-19. These patients were monitored continuously for one month after pathogenesis, treated with enteral nutrition delivered from the tube inserted through the nose. The dotted line denotes the threshold concentration of hypozincemia as 70 µg/dL.

caused by hypozincemia is a well-known fact (Kodama et al., 2016), this state is revealed by the findings that intracellular zinc ion is involved in activating T cells in cell-mediated immunity, as described above. Therefore, hypozincemia may be closely related to events that significantly impact the prognosis of COVID-19; for example, patients with hypozincemia whose natural immunity is low are vulnerable to viral infection. At the same time, once infected, excessive immune reactions can easily cause a cytokine storm or the imbalance between M1 and M2 macrophages that regulate the degree of inflammatory reactions.

According to recent literature from South Korea, the relationships between “general severely ill patients and ICU transfer rate” and “serum trace element levels in patients and their changes over time elapsed” have been investigated in detail. Statistically, a significant number of cases have been confirmed in which severely ill patients, who died after ICU transfer, had hypozincemia and whose serum zinc concentration did not increase after treatment (Lee et al., 2019). The University of Melbourne in Australia has announced on their website that they will begin clinical trials of intravenous injection of zinc chloride for patients with COVID-19 (Ischia et al., 2020). The group of organizers of this prospective clinical study has reported actual cases of inhibiting organ disorders in several organs (lungs, liver, and kidneys) in their previous fundamental research and clinical applications, in which reperfusion disorders in the organs where depleted oxygen supply is caused by ischemia can be treated with intravenous injection of zinc chloride. In other words, organ disorders can be inhibited with oxygenation therapy by intravascular zinc supplementation into the vessels before ischemia-reperfusion (Ischia et al., 2019). Based on these results, they seem to have initiated clinical tests to observe if zinc chloride can positively affect the treatment of COVID-19 (Ischia et al., 2020). Although it is estimated to take approximately one year to report the results of this study, it is expected to determine the effects of zinc supplementation in formal clinical tests.

This study suggested that hypozincemia could be a predictor for a critical illness of COVID-19. However, trials with an increased number of patients should be evaluated; and at the same time, whether zinc salts medication can inhibit viral replication of SARS-CoV-2 and potentially be a therapeutic agent should be verified in prospective clinical trials as described above (Ischia et al., 2020). In Japan, zinc acetate (brand name Nobelzin) as a pharmaceutical drug has been applied to treat Wilson’s disease and hypozincemia, which can be prescribed based on medical doctors’ diagnosis. If the relationship between hypozincemia and the severe cases of COVID-19 in a larger number of patients is identified like this study, it may be useful for the future, to medicate COVID-19 with oral zinc salt therapy. In the context and perspective of prevention

and treatment of COVID-19, we would like to provide the additional result for time-dependent profiles of zinc levels of four critically ill patients in this study who were admitted into ICU, delivered by enteral nutrition from the tube inserted through the nose, observed continuously for one month after pathogenesis, gradually recovered and finally discharged from the hospital, as shown in Figure 5. From this data, it was indicated that after supplying adequate enteral nutrition in ICU, an aggressive and enteral nutrition support for 10–12 days could produce a recovery of serum zinc level over the normal range in critically ill patients.

Additionally, there were no especially adverse effects in these patients. Therefore, we considered it possible to use both zinc supplementation to uninfected people for prevention and zinc medication to patients for treatment who might exhibit lower serum zinc levels than the normal range. However, as the possible adverse effect of zinc administration, excess zinc supply could induce lower copper levels because of each other’s opposing absorption and metabolism in the body. Therefore, additional monitoring of both zinc and copper levels may be needed simultaneously in those cases.

In conclusion, according to the results of measuring serum zinc in patients with COVID-19 at this hospital, most severely ill patients showed subclinical or real zinc deficiency; prolonged hypozincemia can be a risk factor for a severe case of COVID-19. In evaluating the relationship between the serum zinc level and severity of patients with COVID-19 by multivariate logistic regression analysis, it was suggested that the ROC curve with an error rate of 10.3% and AUC of 94.2% by only two factors, serum zinc, and LDH levels, could predict severe cases. Therefore, we would like to emphasize the advantage of measuring the serum zinc level as one of the routine and standard physiological blood tests. Proper management of the prediction results in this study can contribute to establishing and maintaining a safe medical system, taking the arrival of the second wave, and the spread of COVID-19 in the future into consideration.

Funding source

This study did not receive any funding.

Ethical approval

This study involved human subjects; institutional review board (IRB) approval on an opt-out in the clinical observation study was obtained for experimentation with human subjects before starting the research. The work described has been carried out following The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

Conflict of interest

We declare no conflict of interests, no competing financial interests, or personal relationships that could have influenced this study.

References

- Gandhi RT, Lynch JB, Rio CD. Mild or moderate COVID-19. *N Engl J Med* 2020;., doi: <http://dx.doi.org/10.1056/NEJMcp2009249>.
- Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. *N Engl J Med* 2020;., doi:<http://dx.doi.org/10.1056/NEJMoa2012410> NEJMoa2012410.
- Guy RK, DiPaola RS, Romanelli F, Dutch RE. Rapid repurposing of drugs for COVID-19. *Science* 2020;368(6493):829–30.
- Higurashi K. Colorimetric reagent for zinc, ACCURAS AUTO Zn. *Biomed Res Trace Elem* 2015;26(1):7–9.
- Hirano T, Murakami M, Fukada T, Nishida K, Yamasaki S, Suzuki T. Roles of zinc and zinc signaling in immunity: Zinc as an intracellular signaling molecule. *Adv Immunol* 2008;97:149–76, doi:[http://dx.doi.org/10.1016/S0065-2776\(08\)00003-5](http://dx.doi.org/10.1016/S0065-2776(08)00003-5).
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395(10223):497–506.
- Ischia J, Bolton DM, Patel O. Why is it worth testing the ability of zinc to protect against ischaemia reperfusion injury for human application. *Metallomics* 2019;11(8):1330–43.
- Ischia J, Patel O., Eutick M. World-first trial to test benefit of intravenous zinc in COVID-19 fight, April 8, 2020, <https://about.unimelb.edu.au/newsroom/news/2020/april/world-first-trial-to-test-benefit-of-intravenous-zinc-in-covid-19-fight/> (accessed June 24, 2020)
- Jordan RE, Adab P, Cheng KK. COVID-19: risk factors for severe disease and death. *BMJ* 2020;368:m1198, doi:<http://dx.doi.org/10.1136/bmj.m1198>.
- Kido T, Ishiwata K, Suka M, Yanagisawa H. Inflammatory response under zinc deficiency is exacerbated by dysfunction of the T helper type 2 lymphocyte–M2 macrophage pathway. *Immunology* 2019;156(4):356–72.
- Kitabayashi C, Fukada T, Kanamoto M, Ohashi W, Hojyo S, Atsumi T, et al. Zinc suppresses Th17 development via inhibition of STAT3 activation. *Int Immunol* 2010;22(5):375–86.
- Kodama H, Itakura H, Omori H, Sasaki M, Sando K, Takamura T, et al. Guideline for treatment of zinc deficiency, 2016. *J Jpn Soc Clin Nutr* 2016;38(2):104–48.
- Lee YH, Bang ES, Lee JH, Lee JH, Kang DR, Hong J, Lee JH. Serum concentrations of trace elements zinc, copper, selenium, and manganese in critically ill patients. *Biol Trace Elem Res* 2019;188(2):316–25.
- Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020;S0091-6749(20) 30495-4.
- Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. *JAMA Intern. Med* 2020;e202033.
- Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery* 2020;6:16, doi:<http://dx.doi.org/10.1038/s41421-020-0156-0>.
- Russell RM, et al. Chapter 96e. Vitamin and trace mineral deficiency and excess. MINERALS. ZINC. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. *Harrison's Principles of Internal Medicine*. 20th edition New York: McGraw Hill; 2018. p. 96e9–96e10.
- Sakurai H, Kojima Y, Yoshikawa Y, Kawabe K, Yasui H. Antidiabetic vanadium(IV) and zinc (II) complexes. *Coord Chem Rev* 2002;226:187–98.
- Sakurai H, Yoshikawa Y, Yasui H. Current state for the development of metallopharmaceuticals and anti-diabetic metal complexes. *Chem Soc Rev* 2008;37:2383–92.
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A Review. *JAMA* 2020;., doi:<http://dx.doi.org/10.1001/jama.2020.6019>.
- Velthuis AJW, Van den Worm SHE, Sims AC, Baric RS, Snijder EJ, Van Hemert MJ. Zn²⁺ inhibits coronavirus and arterivirus RNA polymerase activity *in vitro* and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog* 2010;6(11):e1001176.
- Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in *in vitro*. *Cell Res* 2020;30(3):269–71.
- Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern Med* 2020a;e200994, doi: <http://dx.doi.org/10.1001/jamainternmed.2020.0994>.
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese center for disease control and prevention. *JAMA* 2020b;323(13):1239–42.
- Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ. Chloroquine is a zinc ionophore. *PLoS One* 2014;9(10):e109180.
- Yan L, Zhang HT, Goncalve J, Xiao Y, Wang M, Guo Y, et al. An interpretable mortality prediction model for COVID-19 patients. *Nat Mach Intell* 2020;2:283–8.
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020;8(5):475–81.
- Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China. *Clin Microbiol Infect* 2020;26(6):767–72.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395(10229):1054–62.
- Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. *Cell Metab* 2020;31(6):1068–77.